Get the Stockscreener App
25.50
2.25%
0.56
Celldex Therapeutics Inc stock is traded at $25.50, with a volume of 1.40M.
It is up +2.25% in the last 24 hours and up +11.60% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$24.94
Open:
$25.05
24h Volume:
1.40M
Relative Volume:
1.32
Market Cap:
$1.69B
Revenue:
$9.98M
Net Income/Loss:
$-154.08M
P/E Ratio:
-9.8837
EPS:
-2.58
Net Cash Flow:
$-159.66M
1W Performance:
+23.43%
1M Performance:
+11.60%
6M Performance:
+12.33%
1Y Performance:
-22.96%
1-Day Range:
$24.66
$25.64
1-Week Range:
$19.72
$25.79
52-Week Range:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
25.50 | 1.66B | 9.98M | -154.08M | -159.66M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Pattern recognition hints at Celldex Therapeutics Inc. upsideWeekly Stock Analysis & Weekly Setup with High ROI Potential - Newser
News impact scoring models applied to Celldex Therapeutics Inc.2025 Big Picture & Technical Buy Zone Confirmation - Newser
Can Celldex Therapeutics Inc. hit a new high this monthEarnings Performance Report & Risk Managed Trade Strategies - Newser
Using R and stats models for Celldex Therapeutics Inc. forecasting2025 Earnings Impact & Step-by-Step Trade Execution Guides - Newser
Applying Wyckoff theory to Celldex Therapeutics Inc. stockPortfolio Value Report & Technical Pattern Alert System - Newser
Understanding Celldex Therapeutics Inc.’s price movementIPO Watch & Weekly Watchlist for Hot Stocks - Newser
Real time pattern detection on Celldex Therapeutics Inc. stock2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Will Celldex Therapeutics Inc. continue its uptrendWeekly Risk Report & Growth-Oriented Investment Plans - Newser
Building trade automation scripts for Celldex Therapeutics Inc.Market Movers & Risk Controlled Stock Alerts - Newser
Celldex Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Intraday Action & AI Enhanced Market Trend Forecasts - Newser
Can trapped investors hope for a rebound in Celldex Therapeutics Inc.July 2025 Analyst Calls & Daily Technical Forecast Reports - Newser
What’s the RSI of Celldex Therapeutics Inc. stockIndex Update & Free Weekly Watchlist of Top Performers - thegnnews.com
Top chart patterns to watch in Celldex Therapeutics Inc.Quarterly Performance Summary & Reliable Volume Spike Trade Alerts - Newser
Can volume confirm reversal in Celldex Therapeutics Inc.Portfolio Profit Report & AI Based Buy/Sell Signal Reports - Newser
Trend analysis for Celldex Therapeutics Inc. this weekJuly 2025 Closing Moves & Advanced Swing Trade Entry Alerts - Newser
What to expect from Celldex Therapeutics Inc. in the next 30 daysQuarterly Market Review & Fast Gain Swing Alerts - Newser
What recovery options are there for Celldex Therapeutics Inc.Earnings Recap Report & Verified Chart Pattern Signals - Newser
Celldex Therapeutics Reports Increased R&D Expenses Amid Wider Losses - TipRanks
Celldex Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDollar Strength & Community Driven Trade Alerts - Newser
Assessing Jasper Therapeutics' Earnings Miss and Clinical Pipeline Momentum in a High-Risk, High-Reward Biotech Play - AInvest
Celldex's Barzolvolimab: A Promising Eosinophilic Esophagitis Treatment with Market Potential - AInvest
Buy Signal for Celldex Therapeutics Inc. Stock Key Technical Indicators to WatchMarket Risk Analysis & Verified High Yield Trade Plans - Newser
Celldex Therapeutics (CLDX) Surges 17.2% on Breakthrough Data and Analyst Hype: Is This the Start of a Biotech Renaissance? - AInvest
Is Celldex Therapeutics Inc. trending in predictive chart modelsLow Risk Stock Trade Opportunity Analysis - Newser
Will Celldex Therapeutics Inc. price bounce be sustainablePortfolio Risk Distribution Analysis Tool - Newser
Is Celldex Therapeutics Inc. stock a good hedge against inflationInstitutional Holding Behavior Pattern Analysis - Newser
How Celldex Therapeutics Inc. stock performs during market volatilityChart-Based Entry Confirmation for Beginners - Newser
Using portfolio simulators with Celldex Therapeutics Inc. includedFree Daily Picks With Predictable Performance - Newser
Published on: 2025-08-10 21:08:39 - Newser
Celldex Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):